Login to Your Account

Dara Anchors Cancer Line; Buys Approved Skin Therapy

By Catherine Shaffer
Staff Writer

Tuesday, March 27, 2012
Successful commercialized products have become one of the hottest new survival strategies for biotech pipelines in the new and continuously cautious venture capital environment. Dara Biosciences Inc., of Raleigh, N.C., is securing its future with the acquisition of a solid commercial oncology product through a licensing agreement with Innocutis Holdings LLC.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription